Skip to main content
Erschienen in: Pathology & Oncology Research 2/2017

29.08.2016 | Original Article

17β-hydroxysteroid dehydrogenase type Gene 1937 A > G Polymorphism as a Risk Factor for Cervical Cancer Progression in the Polish Population

verfasst von: Anna Lutkowska, Andrzej Roszak, Pawel P. Jagodziński

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

The role of 17β-estradiol (E2) in the development of cervical tumor (CT) has been demonstrated. 17β Hydroxysteroid dehydrogenase type 1 (HSD17B1) converts estrone (E1) into E2. We aimed to study the distribution of the HSD17B1937 A > G (rs605059) single nucleotide polymorphism (SNP) in women (n = 383) with CT and controls (n = 401) from the Polish population. The p-trend value evaluated for HSD17B1 rs605059 was 0.0233 for all patients. The A/A vs G/G genotype significantly contributed to all patients with CT, and the Odds Ratio (OR) was 1.570 (95 % CI = 1.053–2.343; p = 0.0266). Stratification of the patients based on tumor stage and histological grade indicated the contribution of HSD17B1937 A > G to stages III and IV. The p-value was 0.0010. The OR for the A/A vs G/G genotype was 2.992 (95 % CI = 1.627–5.502, p = 0.0003), the OR for the A/G vs G/G genotype was 2.545 (95 % CI = 1.410–4.593, p = 0.0015) and the OR for the A/A and A/G vs G/G genotype was 2.724 (95 % CI = 1.546–4.799, p = 0.0004). Moreover, we observed a contribution of the rs605059 SNP to histological grade G3 status. The p-value was 0.0042. The OR for the A/A vs G/G genotype was 5.632 (95 % CI = 1.644–19.290, p = 0.0026), the OR for the A/G vs G/G genotype was 4.213 (95 % CI = 1.244–14.265, p = 0.0113) and the OR for the A/A and A/G vs G/G genotype was 4.780 (95 % CI = 1.456–15.687, p = 0.0033). Our study indicated that the HSD17B1937 A > G transition is a risk factor for CT, especially for stages III and IV and histological grade G3.
Literatur
1.
Zurück zum Zitat Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M (2011) Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378:1461–1484CrossRefPubMed Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M (2011) Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378:1461–1484CrossRefPubMed
2.
Zurück zum Zitat Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19CrossRefPubMed Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19CrossRefPubMed
3.
Zurück zum Zitat Nguyen HP, Ramírez-Fort MK, Rady PL (2014) The biology of human papillomaviruses. Curr Probl Dermatol 45:19–32CrossRefPubMed Nguyen HP, Ramírez-Fort MK, Rady PL (2014) The biology of human papillomaviruses. Curr Probl Dermatol 45:19–32CrossRefPubMed
4.
Zurück zum Zitat Moody CA, Laimins LA (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10:550–560CrossRefPubMed Moody CA, Laimins LA (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10:550–560CrossRefPubMed
5.
Zurück zum Zitat Kasap B, Yetimalar H, Keklik A, Yildiz A, Cukurova K, Soylu F (2011) Prevalence and risk factors for human papillomavirus DNA in cervical cytology. Eur J Obstet Gynecol Reprod Biol 159:168–171CrossRefPubMed Kasap B, Yetimalar H, Keklik A, Yildiz A, Cukurova K, Soylu F (2011) Prevalence and risk factors for human papillomavirus DNA in cervical cytology. Eur J Obstet Gynecol Reprod Biol 159:168–171CrossRefPubMed
6.
Zurück zum Zitat International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, de Berrington González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370:1609–1621CrossRef International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, de Berrington González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370:1609–1621CrossRef
7.
Zurück zum Zitat Castellsague X, Munoz N (2003) Chapter 3: cofactors in human papillomavirus carcinogenesis—role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr:20–28 Castellsague X, Munoz N (2003) Chapter 3: cofactors in human papillomavirus carcinogenesis—role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr:20–28
8.
Zurück zum Zitat Almonte M, Albero G, Molano M, Carcamo C, García PJ, Pérez G (2008) Risk factors for human papillomavirus exposure and co factors for cervical cancer in Latin America and the Caribbean. Vaccine 26:L16–L36CrossRefPubMed Almonte M, Albero G, Molano M, Carcamo C, García PJ, Pérez G (2008) Risk factors for human papillomavirus exposure and co factors for cervical cancer in Latin America and the Caribbean. Vaccine 26:L16–L36CrossRefPubMed
9.
Zurück zum Zitat Deligeoroglou E, Giannouli A, Athanasopoulos N, Karountzos V, Vatopoulou A, Dimopoulos K, Creatsas G (2013) HPV infection: Immunological aspects and their utility in future therapy. Infect Dis Obstet Gynecol 2013:540850CrossRefPubMedPubMedCentral Deligeoroglou E, Giannouli A, Athanasopoulos N, Karountzos V, Vatopoulou A, Dimopoulos K, Creatsas G (2013) HPV infection: Immunological aspects and their utility in future therapy. Infect Dis Obstet Gynecol 2013:540850CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Ault KA (2006) Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006:40470CrossRefPubMedPubMedCentral Ault KA (2006) Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006:40470CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat De Azambuja K, Barman P, Toyama J, Elashoff D, Lawson GW, Williams LK, Chua K, Lee D, Kehoe JJ, Brodkorb A, Schwiebert R, Kitchen S, Bhimani A, Wiley DJ (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761–767PubMed De Azambuja K, Barman P, Toyama J, Elashoff D, Lawson GW, Williams LK, Chua K, Lee D, Kehoe JJ, Brodkorb A, Schwiebert R, Kitchen S, Bhimani A, Wiley DJ (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761–767PubMed
12.
Zurück zum Zitat Shai A, Brake T, Somoza C, Lambert PF (2007) The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res 67:1626–1635CrossRefPubMedPubMedCentral Shai A, Brake T, Somoza C, Lambert PF (2007) The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res 67:1626–1635CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM (2000) Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res 60:1267–1275PubMed Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM (2000) Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res 60:1267–1275PubMed
14.
Zurück zum Zitat Cortés-Malagón EM, Bonilla-Delgado J, Díaz-Chávez J, Hidalgo-Miranda A, Romero-Cordoba S, Uren A, Celik H, McCormick M, Munguía-Moreno JA, Ibarra-Sierra E, Escobar-Herrera J, Lambert PF, Mendoza-Villanueva D, Bermudez-Cruz RM, Gariglio P (2013) Gene expression profile regulated by the HPV16 E7 oncoprotein and estradiol in cervical tissue. Virology 447:155–165CrossRefPubMedPubMedCentral Cortés-Malagón EM, Bonilla-Delgado J, Díaz-Chávez J, Hidalgo-Miranda A, Romero-Cordoba S, Uren A, Celik H, McCormick M, Munguía-Moreno JA, Ibarra-Sierra E, Escobar-Herrera J, Lambert PF, Mendoza-Villanueva D, Bermudez-Cruz RM, Gariglio P (2013) Gene expression profile regulated by the HPV16 E7 oncoprotein and estradiol in cervical tissue. Virology 447:155–165CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R (1989) Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 70:2227–2232CrossRefPubMed Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R (1989) Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 70:2227–2232CrossRefPubMed
16.
Zurück zum Zitat Correa I, Cerbón MA, Salazar AM, Solano JD, García-Carrancá A, Quintero A (2002) Differential p53 protein expression level in human cancer-derived cell lines after estradiol treatment. Arch Med Res 33:455–459CrossRefPubMed Correa I, Cerbón MA, Salazar AM, Solano JD, García-Carrancá A, Quintero A (2002) Differential p53 protein expression level in human cancer-derived cell lines after estradiol treatment. Arch Med Res 33:455–459CrossRefPubMed
17.
Zurück zum Zitat Ruutu M, Wahlroos N, Syrjänen K, Johansson B, Syrjänen S (2006) Effects of 17beta-estradiol and progesterone on transcription of human papillomavirus 16 E6/E7 oncogenes in CaSki and SiHa cell lines. Int J Gynecol Cancer 16:1261–1268CrossRefPubMed Ruutu M, Wahlroos N, Syrjänen K, Johansson B, Syrjänen S (2006) Effects of 17beta-estradiol and progesterone on transcription of human papillomavirus 16 E6/E7 oncogenes in CaSki and SiHa cell lines. Int J Gynecol Cancer 16:1261–1268CrossRefPubMed
18.
Zurück zum Zitat Wang Q, Li X, Wang L, Feng YH, Zeng R, Gorodeski G (2004) Antiapoptotic effects of estrogen in normal and cancer human cervical epithelial cells. Endocrinology 145:5568–5579CrossRefPubMed Wang Q, Li X, Wang L, Feng YH, Zeng R, Gorodeski G (2004) Antiapoptotic effects of estrogen in normal and cancer human cervical epithelial cells. Endocrinology 145:5568–5579CrossRefPubMed
19.
Zurück zum Zitat Huang Y, Li J, Xiang L, Han D, Shen X, Wu X (2012) 17β-Oestradiol activates proteolysis and increases invasion through phosphatidylinositol 3-kinase pathway in human cervical cancer cells. Eur J Obstet Gynecol Reprod Biol 165:307–312CrossRefPubMed Huang Y, Li J, Xiang L, Han D, Shen X, Wu X (2012) 17β-Oestradiol activates proteolysis and increases invasion through phosphatidylinositol 3-kinase pathway in human cervical cancer cells. Eur J Obstet Gynecol Reprod Biol 165:307–312CrossRefPubMed
20.
Zurück zum Zitat Arbeit JM, Howley PM, Hanahan D (1996) Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A 93:2930–2935CrossRefPubMedPubMedCentral Arbeit JM, Howley PM, Hanahan D (1996) Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A 93:2930–2935CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Brake T, Lambert PF (2005) Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A 102:2490–2495CrossRefPubMedPubMedCentral Brake T, Lambert PF (2005) Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A 102:2490–2495CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Simpson ER (2003) Sources of estrogen and their importance. J Steroid Biochem Mol Biol 86:225–230CrossRefPubMed Simpson ER (2003) Sources of estrogen and their importance. J Steroid Biochem Mol Biol 86:225–230CrossRefPubMed
23.
Zurück zum Zitat Simpson E, Rubin G, Clyne C, Robertson K, O’Donnell L, Davis S, Jones M (1999) Local estrogenbiosynthesis in males and females. Endocr Relat Cancer 6:131–137CrossRefPubMed Simpson E, Rubin G, Clyne C, Robertson K, O’Donnell L, Davis S, Jones M (1999) Local estrogenbiosynthesis in males and females. Endocr Relat Cancer 6:131–137CrossRefPubMed
24.
Zurück zum Zitat Luu-The V, Labrie F (2010) The intracrine sex steroid biosynthesis pathways. Prog Brain Res 181:177–192CrossRefPubMed Luu-The V, Labrie F (2010) The intracrine sex steroid biosynthesis pathways. Prog Brain Res 181:177–192CrossRefPubMed
25.
Zurück zum Zitat Lukacik P, Kavanagh KL, Oppermann U (2006) Structure and function of human 17-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 248:61–71CrossRefPubMed Lukacik P, Kavanagh KL, Oppermann U (2006) Structure and function of human 17-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 248:61–71CrossRefPubMed
26.
Zurück zum Zitat Vihko P, Isomaa V, Ghosh D (2001) Structure and function of 17beta-hydroxysteroid dehydrogenase type 1 and type 2. Mol Cell Endocrinol 171:71–76CrossRefPubMed Vihko P, Isomaa V, Ghosh D (2001) Structure and function of 17beta-hydroxysteroid dehydrogenase type 1 and type 2. Mol Cell Endocrinol 171:71–76CrossRefPubMed
27.
Zurück zum Zitat Sawetawan C, Milewich L, Word RA, Carr BR, Rainey WE (1994) Compartmentalization of type I 17β-hydroxysteroid oxidoreductase in the human ovary. Mol Cell Endocrinol 99:161–168CrossRefPubMed Sawetawan C, Milewich L, Word RA, Carr BR, Rainey WE (1994) Compartmentalization of type I 17β-hydroxysteroid oxidoreductase in the human ovary. Mol Cell Endocrinol 99:161–168CrossRefPubMed
28.
Zurück zum Zitat Fournet-Dulguerov N, MacLusky NJ, Leranth CZ, Todd R, Mendelson CR, Simpson ER, Naftolin F (1987) Immunohistochemical localization of aromatase cytochrome P-450 and estradiol dehydrogenase in the syncytiotrophoblast of the human placenta. J Clin Endocrinol Metab 65:757–764CrossRefPubMed Fournet-Dulguerov N, MacLusky NJ, Leranth CZ, Todd R, Mendelson CR, Simpson ER, Naftolin F (1987) Immunohistochemical localization of aromatase cytochrome P-450 and estradiol dehydrogenase in the syncytiotrophoblast of the human placenta. J Clin Endocrinol Metab 65:757–764CrossRefPubMed
29.
Zurück zum Zitat Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE (2001) Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 61:785–789PubMed Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE (2001) Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 61:785–789PubMed
30.
Zurück zum Zitat AH W, Seow A, Arakawa K, Van Den Berg D, Lee HP, MC Y (2003) HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 104:450–457CrossRef AH W, Seow A, Arakawa K, Van Den Berg D, Lee HP, MC Y (2003) HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 104:450–457CrossRef
31.
Zurück zum Zitat Yao L, Cao LH, Qiu LX, Yu L (2010) The association between HSD17B1 Ser312Gly polymorphism and breast cancer risk: a meta-analysis including 31,053 subjects. Breast Cancer Res Treat 123:577–580CrossRefPubMed Yao L, Cao LH, Qiu LX, Yu L (2010) The association between HSD17B1 Ser312Gly polymorphism and breast cancer risk: a meta-analysis including 31,053 subjects. Breast Cancer Res Treat 123:577–580CrossRefPubMed
32.
Zurück zum Zitat Kato I, Cichon M, Yee CL, Land S, Korczak JF (2009) African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer. Cancer Epidemiol 33:24–30CrossRefPubMedPubMedCentral Kato I, Cichon M, Yee CL, Land S, Korczak JF (2009) African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer. Cancer Epidemiol 33:24–30CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Obazee O, Justenhoven C, Winter S, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Hannelius U, Li J, Humphreys K, Hall P, Giles G, Severi G, Baglietto L, Southey M, Rabstein S, Harth V, Lotz A, Pesch B, Brüning T, Baisch C, Ko YD, Hamann U, Brauch H (2013) Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant. Breast Cancer Res Treat 138:543–548CrossRefPubMed Obazee O, Justenhoven C, Winter S, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Hannelius U, Li J, Humphreys K, Hall P, Giles G, Severi G, Baglietto L, Southey M, Rabstein S, Harth V, Lotz A, Pesch B, Brüning T, Baisch C, Ko YD, Hamann U, Brauch H (2013) Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant. Breast Cancer Res Treat 138:543–548CrossRefPubMed
34.
Zurück zum Zitat Iwasaki M, Hamada GS, Nishimoto IN, Netto MM, Motola J Jr, Laginha FM, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, Kusama R, Kobayashi M, Ishihara J, Yamamoto S, Hanaoka T, Tsugane S (2010) Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. Nutr Cancer 62:466–475 Iwasaki M, Hamada GS, Nishimoto IN, Netto MM, Motola J Jr, Laginha FM, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, Kusama R, Kobayashi M, Ishihara J, Yamamoto S, Hanaoka T, Tsugane S (2010) Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. Nutr Cancer 62:466–475
35.
Zurück zum Zitat Luu-The V (2001) Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 76:143–151CrossRefPubMed Luu-The V (2001) Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 76:143–151CrossRefPubMed
36.
Zurück zum Zitat Miettinen M, Mustonen M, Poutanen M, Isomaa V, Wickman M, Söderqvist G, Vihko R, Vihko P (1999) 17Beta-hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Res Treat 57:175–182CrossRefPubMed Miettinen M, Mustonen M, Poutanen M, Isomaa V, Wickman M, Söderqvist G, Vihko R, Vihko P (1999) 17Beta-hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Res Treat 57:175–182CrossRefPubMed
37.
Zurück zum Zitat Vihko P, Härkönen P, Soronen P, Törn S, Herrala A, Kurkela R, Pulkka A, Oduwole O, Isomaa V (2004) 17 beta-hydroxysteroid dehydrogenases--their role in pathophysiology. Mol Cell Endocrinol 215:83–88CrossRefPubMed Vihko P, Härkönen P, Soronen P, Törn S, Herrala A, Kurkela R, Pulkka A, Oduwole O, Isomaa V (2004) 17 beta-hydroxysteroid dehydrogenases--their role in pathophysiology. Mol Cell Endocrinol 215:83–88CrossRefPubMed
38.
Zurück zum Zitat Tomaszewska A, Roszak A, Pawlik P, Sajdak S, Jagodziński PP (2015) Increased 17ß-hydroxysteroid dehydrogenase type 1 levels in primary cervical cancer. Biomed Pharmacother 72:179–183CrossRefPubMed Tomaszewska A, Roszak A, Pawlik P, Sajdak S, Jagodziński PP (2015) Increased 17ß-hydroxysteroid dehydrogenase type 1 levels in primary cervical cancer. Biomed Pharmacother 72:179–183CrossRefPubMed
39.
Zurück zum Zitat Jaakkola S, Pukkala E, Lyytinen HK, Ylikorkala O (2012) Postmenopausal estradiol–progestagen therapy and risk for uterine cervical cancer. Int J Cancer 131:E537–E543CrossRefPubMed Jaakkola S, Pukkala E, Lyytinen HK, Ylikorkala O (2012) Postmenopausal estradiol–progestagen therapy and risk for uterine cervical cancer. Int J Cancer 131:E537–E543CrossRefPubMed
40.
Zurück zum Zitat Cong RJ, Huang ZY, Cong L, Ye Y, Wang Z, Zha L, Cao LP, XW S, Yan J, Li YB (2012) Polymorphisms in genes HSD17B1 and HSD17B2 and uterine leiomyoma risk in Chinese women. Arch Gynecol Obstet 286:701–705CrossRefPubMed Cong RJ, Huang ZY, Cong L, Ye Y, Wang Z, Zha L, Cao LP, XW S, Yan J, Li YB (2012) Polymorphisms in genes HSD17B1 and HSD17B2 and uterine leiomyoma risk in Chinese women. Arch Gynecol Obstet 286:701–705CrossRefPubMed
41.
Zurück zum Zitat Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I (2004) HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomark Prev 13:213–219CrossRef Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I (2004) HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomark Prev 13:213–219CrossRef
42.
Zurück zum Zitat Rinaldi S, Plummer M, Biessy C, Castellsagué X, Overvad K, Krüger Kjær S, Tjønneland A, Clavel-Chapelon F, Chabbert-Buffet N, Mesrine S, Lukanova A, Kaaks R, Weikert C, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Agnoli C, Tumino R, Vineis P, Panico S, Bueno-de-Mesquita B, van Kranen HJ, Peeters PH, Bakken K, Lund E, Gram IT, Rodríguez L, Bosch FX, Sánchez MJ, Dorronsoro M, Navarro C, Gurrea AB, Kjellberg L, Dillner J, Manjer J, Butt S, Khaw KT, Wareham N, Allen NE, Travis R, Romieu I, Ferrari P, Riboli E, Franceschi S (2011) Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study. Cancer Epidemiol Biomark Prev 20:2532–2540CrossRef Rinaldi S, Plummer M, Biessy C, Castellsagué X, Overvad K, Krüger Kjær S, Tjønneland A, Clavel-Chapelon F, Chabbert-Buffet N, Mesrine S, Lukanova A, Kaaks R, Weikert C, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Agnoli C, Tumino R, Vineis P, Panico S, Bueno-de-Mesquita B, van Kranen HJ, Peeters PH, Bakken K, Lund E, Gram IT, Rodríguez L, Bosch FX, Sánchez MJ, Dorronsoro M, Navarro C, Gurrea AB, Kjellberg L, Dillner J, Manjer J, Butt S, Khaw KT, Wareham N, Allen NE, Travis R, Romieu I, Ferrari P, Riboli E, Franceschi S (2011) Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study. Cancer Epidemiol Biomark Prev 20:2532–2540CrossRef
Metadaten
Titel
17β-hydroxysteroid dehydrogenase type Gene 1937 A > G Polymorphism as a Risk Factor for Cervical Cancer Progression in the Polish Population
verfasst von
Anna Lutkowska
Andrzej Roszak
Pawel P. Jagodziński
Publikationsdatum
29.08.2016
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2017
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0103-4

Weitere Artikel der Ausgabe 2/2017

Pathology & Oncology Research 2/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.